The findings also revealed very differentiated expression of CAIX and CAXII in the different CMS groups, further confirming that assessing the CMS groups in CRC patients is very important to provide the patient with the most beneficial additional anti-tumor treatment, e.g., in the form of SLC-0111 if the CAIX/CAXII expression in the tumor mass is high, as in a CMS3 tumor. Here, CA9 is linked to colorectal carcinoma.